AbTx

French tech company | Builders Republic

About

Preclinical biotech developing miniaturised antibody-drug conjugates for solid tumours — its patented Therano-Stick platform grafts payloads onto an engineered glutamine tag by microbial transglutaminase, producing Fragment Drug Conjugates (Fab, scFv, VHH) that reach tissue full-length antibodies penetrate poorly, with lead programme AbTx101 aimed at pancreatic cancer.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Pre-seed
Founded
2024
City
DIJON
Region
Bourgogne-Franche-Comté
Tracked rounds
1
Amount raised
1.7 M€

Funding rounds

  • Pre-seed · 2026

Investors